<DOC>
	<DOCNO>NCT01115608</DOCNO>
	<brief_summary>It well know secondary prevention important patient establish coronary heart disease , reduce mortality morbidity . Pharmacists Norway routinely involve follow-up patient group , many study show involvement pharmacist positive influence achieve therapy goal e.g . blood pressure , lipid blood sugar . The investigator hypothesis follow-up clinical pharmacist hospital discharge increase adherence clinical guideline recommendation increase achievement specific therapy goal blood pressure , lipid glucose patient establish CHD . The investigator plan include patient establish CHD , discharge hospital admission cardiology department . Patients include ( 18-80 year ) randomize intervention control group . In addition ordinary health care , intervention group receive follow-up clinical pharmacist one year three meeting point , discharge , three month one year . The control group receive ordinary health care , call one year data collection . Patients live nursing home , patient already receive pharmaceutical follow-up elsewhere cancer patient exclude study . Only patient live area Tromsoe nearby include , need physically see pharmacist . The follow-up include medication review subsequently solve drug relate problem addition drug information monitor clinical therapy goal relevant secondary prevention CHD . The main outcome measure adherence specify review criterion define medication assessment tool ( MAT-CHDsp ) base recommendation European Society Cardiology . Other outcome measure include 1 ) number drug relate problem identify solve , 2 ) hospital admission , 3 ) death .</brief_summary>
	<brief_title>Pharmaceutical Follow-up Coronary Heart Disease ( CHD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>establish coronary heart disease age 18 80 year patient live three nearby community Tromsoe , Balsfjord Karlsoey , need see pharmacist personally . patient live nursing home patient include NORstent , another trial include patient department patient already receive pharmaceutical followup elsewhere cancer patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Preventive Health Services</keyword>
</DOC>